Association between incretin-related drugs and fractures in patients treated with pioglitazone: A pharmacovigilance study using the FDA Adverse Event Reporting System
Int. Journal of Clinical Pharmacology and Therapeutics · 01.01.2026 · 64 (01) · 1-8
DOI: 10.5414/cp204789 ↗Kurz gefasst
Fachartikel in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, erschienen am 01.01.2026. Verfasst von Katsuhiro Ohyama und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Fractures, Bone, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Ohyama, K., Abe, N., Okamoto, T., & Hori, Y. (2026). Association between incretin-related drugs and fractures in patients treated with pioglitazone: A pharmacovigilance study using the FDA Adverse Event Reporting System. Int. Journal of Clinical Pharmacology and Therapeutics, 64(01), 1-8. https://doi.org/10.5414/cp204789
Vancouver
Ohyama K, Abe N, Okamoto T, Hori Y. Association between incretin-related drugs and fractures in patients treated with pioglitazone: A pharmacovigilance study using the FDA Adverse Event Reporting System. Int. Journal of Clinical Pharmacology and Therapeutics. 2026;64(01):1-8. doi:10.5414/cp204789
BibTeX
@article{Ohyama2026,
author = {Ohyama, Katsuhiro and Abe, Nonoka and Okamoto, Takumi and Hori, Yusuke},
title = {Association between incretin-related drugs and fractures in patients treated with pioglitazone: A pharmacovigilance study using the FDA Adverse Event Reporting System},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2026},
volume = {64},
number = {01},
pages = {1--8},
doi = {10.5414/cp204789}
}
EUVIMED